Aiming to bring relief and improved quality of life for people with GERD
The objective of our science is clear – developing an effective treatment for people living with gastroesophageal reflux disease (GERD) with unique disease control. The time has now come for the next leap forward in treating acid-related diseases. With the development of our drug candidate, linaprazan glurate, our ambition is to improve the quality of life for these people.
Millions of people around the world suffer from Gastroesophageal reflux disease, GERD. Still, Standard of Care treatment, (SoC), PPI-based drugs, are not effective enough for all types of GERD. Heartburn is a common symptom and in severe stages, pain and other symptoms often occur.
Our drug candidate represents a novel mode of action with an improved pharmacokinetic profile and the potential to have superior efficacy. Linaprazan glurate, a Potassium-Competitive Acid Blocker (P-CAB) is a prodrug of linaprazan, a substance initially developed and tested by AstraZeneca. The gastric acid control ability of linaprazan glurate has in studies shown to be superior to current medication.
The path to value creation
Our goals are set, and we are preparing for the next step in taking linaprazan glurate to the market. After evaluating the results of the ongoing clinical testing phase, we will proceed in developing linaprazan glurate to be an effective treatment for unmet medical needs in eGERD and sGERD.
The ongoing clinical development and testing of linaprazan glurate are showing promising results in acid control and in lowering the C-max value*, minimizing the load to the liver. Follow the progress and further development.